glp-1 receptor agonist brands How medications are transforming diabetes and weight loss treatment GLP-1 Agonists: A Comprehensive Overview
Description
GLP1s that are FDA-approved for the treatment of obesity require prior authorization
The effects of this presentation on weight and glycemia in clinical trials and real-world settings are comparable to those induced by the subcutaneous presentation, although a specific indication for weight control without DT2 is still lacking.86 In order to avoid confusion in daily clinical practice, it is important to note that liraglutide 3mg and semaglutide 2.4mg can be used in patients with DT2, provided these are obese or overweight with comorbidities
Carel W
The medication regimen and medication-taking behavior should be reevaluated at regular intervals (every 3-6 months) and adjusted as needed to incorporate specific factors that impact the choice of treatment
By contrast, GLP-1 receptor agonists delay gastric emptying, but DPP-4 inhibitors do not [6]
